(E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway

[1]  Fei Li,et al.  Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. , 2013, Cancer letters.

[2]  Pushpa Saranya Kollipara,et al.  (E)‐2,4‐bis(p‐hydroxyphenyl)‐2‐butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK‐mediated suppression of NF‐κB and up‐regulation of TNFRSF10B (DR5) , 2013, British journal of pharmacology.

[3]  S. Ngai,et al.  Ovarian Cancer Stem Cells: A New Target for Cancer Therapy , 2013, BioMed research international.

[4]  Ling-li Zhang,et al.  Regulation of AKT gene expression by cisplatin , 2013, Oncology letters.

[5]  M. Park,et al.  Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor κB and signal transducer and activator of transcription 3 , 2012, Archives of Pharmacal Research.

[6]  S. Kim,et al.  AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules , 2012, Amino Acids.

[7]  Y. Yen,et al.  Ovarian Cancer: Opportunity for Targeted Therapy , 2011, Journal of oncology.

[8]  Daowen Wang,et al.  A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer. , 2012, Human gene therapy.

[9]  J. Hong,et al.  Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. , 2012, Toxicology and applied pharmacology.

[10]  C. Rancourt,et al.  Targeted ovarian cancer treatment: the TRAILs of resistance. , 2012, American journal of cancer research.

[11]  J. Hong,et al.  Inhibitory effect of a tyrosine-fructose Maillard reaction product, 2,4-bis(p-hydroxyphenyl)-2-butenal on amyloid-β generation and inflammatory reactions via inhibition of NF-κB and STAT3 activation in cultured astrocytes and microglial BV-2 cells , 2011, Journal of Neuroinflammation.

[12]  M. Nørgaard,et al.  Survival of patients with ovarian cancer in central and northern Denmark, 1998–2009 , 2011, Clinical epidemiology.

[13]  C. Giacomantonio,et al.  Curcumin‐induced apoptosis in ovarian carcinoma cells is p53‐independent and involves p38 mitogen‐activated protein kinase activation and downregulation of Bcl‐2 and survivin expression and Akt signaling , 2010, Molecular carcinogenesis.

[14]  J. Hong,et al.  Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-κB activity via direct interaction with p50 , 2009, Molecular Cancer Therapeutics.

[15]  T. Shanafelt,et al.  Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG , 2009, Clinical Cancer Research.

[16]  E. D. de Vries,et al.  Targeting TRAIL death receptors. , 2008, Current opinion in pharmacology.

[17]  L. Meng,et al.  Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. , 2008, Cancer letters.

[18]  J. Nesland,et al.  Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma , 2007, Cancer.

[19]  L. Ignarro,et al.  Journal of Translational Medicine BioMed Central , 2008 .

[20]  Liz Y. Han,et al.  Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. , 2007, Cancer research.

[21]  M. Smyth,et al.  Targeting death-inducing receptors in cancer therapy , 2007, Oncogene.

[22]  Suyun Huang.  Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications , 2007, Clinical Cancer Research.

[23]  R. Osamura,et al.  Treatment Strategy for Recurrent and Refractory Epithelial Ovarian Cancer: Efficacy of High-Dose Chemotherapy with Hematopoietic Stem Cell Transplantation , 2006, Acta histochemica et cytochemica.

[24]  G. Ouyang,et al.  Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells , 2006, Cell biology international.

[25]  Brendan M Leung,et al.  Chemoresistance in human ovarian cancer: the role of apoptotic regulators , 2003, Reproductive biology and endocrinology : RB&E.

[26]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[27]  E. Partridge,et al.  Epithelial ovarian cancer: Prevention, diagnosis, and treatment , 1999, CA: a cancer journal for clinicians.

[28]  M. Markman.  Ovarian cancer update: management challenges and advances. , 1994, Cleveland Clinic journal of medicine.